Literature DB >> 26343213

Lipoprotein(a): Its relevance to the pediatric population.

Catherine J McNeal1.   

Abstract

Lipoprotein(a) (Lp(a)) is a highly atherogenic and heterogeneous lipoprotein that is inherited in an autosomal codominant trait. A unique aspect of this lipoprotein is that it is fully expressed by the first or second year of life in children, a pattern that is distinctly different from other lipoproteins, which typically only reach adult levels after adolescence. Despite decades of research, Lp(a) metabolism is still poorly understood but what is abundantly clear is that it is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD). The Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents does not recommend measuring Lp(a) levels as part of routine screening except in youth with an ischemic or hemorrhagic stroke or youth with a parental history of ASCVD not explained by classical risk factors. One of the reasons that both the pediatric and adult guidelines fail to include this lipoprotein as part of routine lipid screening is the absence of data to show that lowering Lp(a) will reduce current or future ASCVD risk independently of low-density lipoprotein cholesterol (LDL-C) lowering. The cholesterol carried by Lp(a) is included in the low-density lipoprotein cholesterol measurement, but a separate test is used to measure the lipoprotein mass and/or cholesterol carried only by Lp(a). Because levels seem to be largely under genetic control, studies of lifestyle modification have been inconclusive although one study in obese children showed a decrease in the Lp(a) level comparable with the favorable effect on other lipids. The most compelling data regarding the importance of Lp(a) in the pediatric population are the increased risk associated with arterial ischemic stroke, a risk that is comparable with that associated with antiphospholipid antibodies or protein C deficiency. Although no specific pharmaceutical treatments are recommended to lower Lp(a) levels in youth, it is vitally important to educate youth and their parents about the excessive risk associated with this lipoprotein and the need to avoid the acquisition of other lifestyle-related risk factors such as smoking, excess weight, and physical inactivity to preserve more ideal cardiovascular health in adulthood.
Copyright © 2015 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adolescence; Atherosclerotic cardiovascular diseases; Childhood; Lipoprotein(a); Measurement; Treatment; Youth

Mesh:

Substances:

Year:  2015        PMID: 26343213     DOI: 10.1016/j.jacl.2015.07.006

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  8 in total

1.  Overweight adolescents with type 2 diabetes have significantly higher lipoprotein abnormalities than those with type 1 diabetes.

Authors:  Lynae J Hanks; James Heath Pelham; Shalini Vaid; Krista Casazza; Ambika P Ashraf
Journal:  Diabetes Res Clin Pract       Date:  2016-03-07       Impact factor: 5.602

Review 2.  NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis.

Authors:  Sotirios Tsimikas; Sergio Fazio; Keith C Ferdinand; Henry N Ginsberg; Marlys L Koschinsky; Santica M Marcovina; Patrick M Moriarty; Daniel J Rader; Alan T Remaley; Gissette Reyes-Soffer; Raul D Santos; George Thanassoulis; Joseph L Witztum; Simhan Danthi; Michelle Olive; Lijuan Liu
Journal:  J Am Coll Cardiol       Date:  2018-01-16       Impact factor: 24.094

3.  Lipoprotein(a) Concentrations Correlate With LDL-C in Children With Type 1 and 2 Diabetes.

Authors:  Christy Foster; A K M Fazlur Rahman; Ambika P Ashraf
Journal:  J Endocr Soc       Date:  2021-08-18

Review 4.  There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness.

Authors:  Michael E Makover; Michael D Shapiro; Peter P Toth
Journal:  Am J Prev Cardiol       Date:  2022-08-06

5.  Case Studies in Pediatric Lipid Disorders and Their Management.

Authors:  Ambika P Ashraf; Bhuvana Sunil; Vaneeta Bamba; Emily Breidbart; Preneet Cheema Brar; Stephanie Chung; Anshu Gupta; Aditi Khokhar; Seema Kumar; Marissa Lightbourne; Manmohan K Kamboj; Ryan S Miller; Nivedita Patni; Vandana Raman; Amy S Shah; Don P Wilson; Brenda Kohn
Journal:  J Clin Endocrinol Metab       Date:  2021-11-19       Impact factor: 6.134

6.  Elevated serum lipoprotein(a) as a risk factor for combined intracranial and extracranial artery stenosis in a child with arterial ischemic stroke: A case report.

Authors:  Ji Yoon Han; Hyun Jeong Kim; Soyoung Shin; Joonhong Park; In Goo Lee
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

7.  Longitudinal Assessment of Lipoprotein(a) Levels in Perinatally HIV-Infected Children and Adolescents.

Authors:  Jason G van Genderen; Malon Van den Hof; Claudia G de Boer; Hans P G Jansen; Sander J H van Deventer; Sotirios Tsimikas; Joseph L Witztum; John J P Kastelein; Dasja Pajkrt
Journal:  Viruses       Date:  2021-10-14       Impact factor: 5.048

Review 8.  Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics.

Authors:  Daniel I Swerdlow; David A Rider; Arash Yavari; Marie Wikström Lindholm; Giles V Campion; Steven E Nissen
Journal:  Cardiovasc Res       Date:  2022-03-25       Impact factor: 10.787

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.